---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-26-000008"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:14:23.552530+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeuroPace Q4 rev $26.6M (+24%), FY25 rev $100M (+25%); guides FY26 $98-100M

## Summary
- Q4 2025 revenue $26.6M (+24% YoY); RNS System revenue $22.4M (+26% YoY); gross margin 77.4%.
- Full year 2025 revenue $100.0M (+25% YoY); net loss ($2.7M) Q4; Adj. EBITDA ($5.0M) FY25.
- Submitted PMA-S to FDA for IGE indication expansion; NAUTILUS trial showed 77% median seizure reduction.
- Reiterated FY26 guidance: total rev $98-100M (20-22% RNS growth); Adj. EBITDA ($9-10M).
- DIXI Medical partnership ended Dec 31, 2025; discontinued ops reporting to begin Q1 2026.

## SEC filing metadata
- accession: 0001528287-26-000008
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828726000008/0001528287-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828726000008/npce-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-26-000008
- JSON: https://secwatch.observer/filing/0001528287-26-000008.json
- Plain text: https://secwatch.observer/filing/0001528287-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.